Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Transplant-Related Complications Prof. Ilona Hromadníková, Ph.D. Department of Molecular Biology and Cell Pathology Third Faculty of Medicine, Charles University in Prague Graft versus host reaction • graft versus host disease (GvHD) • major complication after allogeneic transplantation • consequence of incomplete match in HLA system or mismatch in other antigens outside major histocompatibility complex (miHAg), polymorphisms in genes for cytokines and others • result of HLA and miHAg antigen recognition in patient by donor‘s T lymphocytes → leading to tissue damage • host versus graft reaction = recognition of donor‘s HLA and miHAg antigens by the patient, often ends with rejection Circumstances for GvHD development • graft contains immunocompetent cells, mature T lymphocytes GvHD correlates with the number of donor‘s T lymphocytes • recipient expresses tissue antigens which donor doesn‘t have HLA strongly stimulate allogeneic T lymphocytes miHAg can induce GvHD even in HLA-identical transplants • rare development in autologous and syngeneic Tx – recognition of own antigens as foreign leads to the induction of autoimmune process • development after solid organ Tx containing lymphatic tissue • development after blood transfusion: donor homozygous for one recipient‘s haplotype recognizes antigens from the other haplotype Non-HLA immunogenetics and GvHD • minor histocompatibility antigens peptides derived from intracellular proteins presented by HLA - male specific mHAg encoded by Y chromosome complicates HLA-identical Tx in setting from female to male - other mHAg expressed on hematopoetic cells (HA-1, HA-2) or other tissues (H-Y, HA-3), mismatch in HA-1, -2, -4, -5 associated with↑ risk of GvHD • polymorphisms in genes for cytokines and genes with relation to immune system ↑ pro-inflammatory cytokine expression (TNF-a, IL-6, IFN-g) – risk of GvHD, antiinflammatory (IL-10, IL-1Ra) – protective effects • polymorphisms of other genes polymorphism in vitamin D receptor and estrogen receptor – association with GvHD development Polymorphisms in cytokine genes in regulatory region of the gene → high/low cytokine production TNFd3 pro-inflammatory function, ↑ TNF-a production P: ↑ aGvHD risk in HLA identical sibling BMT TNF receptor unknown function (TNFRII receptor stimulates T cell proliferation and alloimmune response) D: more severe GvHD in MUD HSCT P: ↑ aGvHD risk in HLA identical sibling BMT IL-10 anti-inflammatory function, haplotype association with ↓ production P: ↑ GvHD risk in BMT, P&D: association with aGvHD IL-6 pro-inflammatory function, allele G associated with↑production P: ↑ a,cGvHD risk in HLA identical sibling Tx IFN-g pro-inflammatory function, lower production in vitro Intron 1 P: ↑ aGvHD risk in HLA identical sibling Tx IL-1 pro-inflammatory function, D: ↑ cGvHD risk in HLA identical IL-1a 889;intron 6 VNTR sibling Tx Acute GvHD • develops usually within 2 – 5 weeks post Tx (until D+100) • also earlier – hyperacute GvHD, reason is HLA non-identical graft • in 30-60% cases of HLA identical sibling Tx despite of immunosuppressive prophylaxis • depends on number of T lymphocytes in graft, donor allosensibilization, patient‘s age, conditioning type and prevention methods of GvHD development • most frequently involved organs: skin, liver, GIT frequent involvement of epithelial surfaces: conjunctiva, esophagus and vagina aGvHD pathophysiology • Phase 1: donor T-cell infusion patient damaged by underlying disease, infection and particularly by the conditioning regimen → result in activation of host cells: secretion of proinflammatory cytokines (TNF-a, IL-1) with consequences of increased expression of adhesion molecules and HLA antigens • Phase 2: T-cell activation 2a. donor T-cell interaction with host APCs → proliferation, differentiation and secretion of cytokines (IL-2, IFN-g) 2b.IL-2, IFN-g enhance T-cell expansion, induce CTL and NK cell responses, activate phagocytes to produce TNF-a and IL-1 2c. TNF-a and IL-1 activate proinflammatory chemokines → thus recruiting effector cells into target organs aGvHD pathophysiology • Phase 3: cellular and inflammatory effector phase complex cascade of multiple effectors (CTLs, NK cells) and inflammatory effectors (TNF-a, IL-1), complex inflammatory response secondary signal for macrophages provided by LPS leaking through intestinal mucosa damaged during phase 1 result in tissue destruction Ferrara et al., 1997 Clinical manifestation of aGvHD • skin involvement maculo-papular rash, can spread and involve the entire body surface with desquamation • GIT involvement anorexia, nausea, diarrhea, abdominal pain, paralytic ileus • liver involvement hyperbilirubinemia, increase of transaminases and alkaline phosphatase • infection severe immunodefficiency – poor resistance against infection Patient with acute skin GvHD of grade 4 resistant to steroid treatment a) epidermolysis, at D+2 of Alefacept treatment (inhibits T-cell activation) b) almost complete epithelialization of the skin, only mild GvHD activity at D+7 of Alefacept treatment c) exacerbation at D+9 of Alefacept treatment, including markedly increased solar erythema d) D+19, complete remission aGvHD grading system • • • • results from stages of skin, liver and GIT involvement usually predicts the clinical course and prognosis mild form – mild morbidity, almost without mortality more severe stages – mortality elevation, up to 100% Grading system of organ involvement for acute GvHD skin GIT liver rash diarrhea bilirubin % of body surface in l/24 h mmol/l < 25% 0.5 l 12 - 20 1 25 - 50% 1.0 l 20 - 50 2 > 50% ≥ 1.5 l > 50 3 desquamation stage pain, ileus AST, ALT elevation 4 Overall grading system for acute GvHD according to the degree of individual organ involvement skin GIT liver grade 1-2 - - I 1-3 1 1 II 2-3 2-3 2-3 III 2-4 2-4 2-3 IV Treatment of aGvHD • treatment and prophylaxis – immunosuppressives: corticosteroids cyclosporine A anti-thymocyte globulin monoclonal antibodies (against CD25, IL-2, TNF – combination) immunotoxins FK506 (tacrolimus) thalidomide UV radiation (photophoresis – extracorporal photochemotherapy) Treatment of aGvHD • mild forms (skin rash) overall treatment is not necessary local treatment with corticosteroid cremes • extensive rash, overall symptoms, liver and gut involvement overall treatment is necessary high corticosteroid doses (methylprednisolon 1 g/m2/day in 1 or 2 doses) over 3 days good responders – reducing to a half dose every 3rd day new intensification treatment in case of progression more severe forms of GvHD often followed by infection with fever Treatment of aGvHD infection – elevation of CRP in bacterial (not in viral and mycotic) infection antibiotics (e.g. ceftazidime with aminoglycosides) no responders to corticoids: resistant aGvHD with unfavourable prognosis (high mortality) possible transition to chronic GvHD treatment with monoclonal antibodies can be effective low long-term survival (cca 20%) Treatment of aGvHD FK506 (tacrolimus) • blocks T-cell activation • effective in preventing and treatment of rejection in solid organ Tx • treatment of aGvHD – significant improvement of skin and gut symptoms lower effect on liver GvHD • extensive nephrotoxicity and neurotoxicity Chronic GvHD • result of later phase of allogeneic Tx • develops newly or after aGvHD (occurence after day 100 post Tx) • in 30 – 60% of patients • risk of development: incomplete match in HLA antigens higher patient‘s age previous aGvHD donor leukocyte infusion CMV infection donor‘s seropositivity for CMV Early chronic GvHD diagnostics Examination physical examination of the skin skin biopsy skin biopsy - direct fluorescence oral biopsy oral biopsy - direct fluorescence eye tests Finding changes in pigmentation or erythema necrotic keratinocytes with eozinophilic cytoplasma, basal cell vacuolization deposits of IgM or C3 along the dermo-epidermal junction mucositis and/or sialadenitis cytoid bodies, deposits of J chain of immunoglobuline Schirmer test < 10 mm, epithelial cornea lesis • small ability of defence against infection • skin changes - papulo-squamous-like dermatitis with pigmentation defect, frequent failure in hair and nail growth • later stages: image similar to sclerodermia, SLE, Sjögren syndrome, rheumatoid arthritis and primary biliary cirrhosis • in cca 80% of patients cholestatic hepatopathy • severe involvement of oral and esophageal mucosa → malnutrition, sicca syndrome development Grading system for cGvHD • Extensive cGvHD - bioptic demonstration of generalized skin involvement or - bioptic demonstration of localized skin involvement and/or liver abnormality due to GvHD plus some of the other indicator: a) bioptic demonstration of aggressive liver involvement b) ocular sicca syndrome (dryness) c) bioptic demonstration of oral mucosis involvement d) demonstration of other organs involvement • Limited cGvHD localized skin involvement and/or liver dysfunction due to cGvHD Treatment of cGvHD 1. corticosteroids (prednisolon 20 – 40 mg/day) 2. cyclosporine A – regular check of blood levels necessary 3. their combination in case of incomplete response 4. thalidomide sedative with antiinflammatory and immunosuppressive effect inhibition of TNF-a production, suppressor cell induction attenuation, constipation, paresthesia 5. irradiation of lymphatic system (TLI) 6. penicillamine in refractery forms with sclerosing skin involvement, influences fibrotic changes and collagen deposits 7. FK506 simultaneous usage of cotrimoxazole or pentamidine to prevent pneumocystic infection Local treatment of cGvHD • • • • • skin changes – corticoids eye dryness – artificial tears limited movement – exercising, physiotherapy contractures – surgical reparation in stabilized GvHD refractory chronic skin manifestations – PUVA (psoralen with UV irradiation - photopheresis – extracorporal photochemotherapy) Supportive treatment during cGvHD • Pneumocystis carinii infection prevention – during corticoid treatment • hypogamaglobulinemia – treatment with immunoglobulines • ovarial hormone substitution – especially after TBI and busulphan • calcium supply – prevention of osteoporosis development • growth hormone substitution • sicca syndrome treatment (artificial tears and saliva, bubble gum, vagina lubricans) • treatment of liver involvement with ursodeoxycholic acid • protection against solar radiation - cremes • rational vaccination Prognostic factors in cGvHD Factor favourable unfavourable GvHD range limited extensive patient‘s age < 20 years > 20 years aGvHD grade 0-I II-IV de novo progressive > 100 < 100 > 100x109/l < 100x109/l type of cGvHD during the onset day of the onset of cGvHD thrombocyte number Treatment response after 9 months complete remission no response Most important prognostic factors: development from acute GvHD lichenoid skin changes bilirubin elevation persistant thrombocytopenia negative response to the treatment with 2 or more risk factors survives cca 20% of patients GvHD in autologous and syngeneic Tx • • • • • possible development of GvHD-like syndrome predominant skin involvement development most frequently after conditioning with TBI development probably due to thymus dysfunction mild manifestation, treatment with corticoids GvHD prevention • HLA compatibility • post-Tx immunosuppression: glucocorticoids – IL-1 attenuation methotrexate – inhibition of cell division and clonal expansion of T cells cyclosporine A – inhibition of IL-2 synthesis, T-cell activation rapamycin, deoxyspergualin, mizoribin, leflunomid • T-cell depletion in graft – milder course of GvHD, missing GvL effect! • Campath-1 (CDw52) antibodies – T-cell elimination, nonengraftment and risk of relapse • Tx of separated CD34+ stem cells • cytokine inhibition Sinusoidal obstructive syndrome (Veno-occlusive liver disease) • toxic damage of sinusoidal endothelia due to conditioning regimen characterized by: jaundice, liquid retainment and putting on the weight (edema), usual painful hepatomegaly • unknown pathogenesis, hepatocyte involvement probably due to accumulation of toxic metabolites of certain conditioning regimen drugs • usually within 14 days post Tx • severe cases: SOS with MOF (multiorgan failure) – thrombocytopenia, pleural effusion, progressive renal, cardiac and pulmonary failure, wooziness, encephalopathy, coma • diagnostics – clinical symptoms: bilirubin level, hepatomegaly, weight gain • differential diagnosis – exclusion: infection, aGvHD, drug toxicity, etc. Infection • risk early after Tx, especially in aplastic phase • microorganisms (MO), by which patient was previously colonized • prevention by patient isolation • prevention of granulocytopenic infection with selective suppression of potencially pathogenic MO → ATB against G- bacteria antimycotics concurrently 3 days prior starting conditioning regimen untill granulocyte elevation > 0.5x109/l • prevention of a-hemolytic streptococcal infection from D+10 - ATB Early phase of infectious risk • lasts cca 3 weeks, neutropenia period prior to engraftment • Damage of innate immunity barriers with conditioning → development of oropharyngeal mucosa inflammation, gastroenteritis, pneumonia and dermatitis • central catheter - source of infection • transient immune defficiency due to T- and B-cell ablation, intensification of immunusuppression with GvHD prophylaxis • neutrophile decline below 0.5x109/l, most severe infection below 0.1x109/l → GIT mucosa and respiratory tract involvement, mostly of endogenous origin sepsis • local infection rare – without inflammation, missing purulency Early phase of infectious risk • after engraftment lower risk of bacterial complications, if GvHD does not develop • etiological agents of mycotic infection: Candida and Aspergillus (Mucoraceae, Fusarin, Cryptococcus, Coccidia, Histoplasma) not easy dg. of systemic infection – demonstration of fungal antigens besides cultivation • viral infections herpes simplex virus activation – involvement of oropharyngeal mucosa, good treatment response Intermediate phase of infectious risk • period from engraftment at least to the 3rd – 4th month post Tx • cell and humoral immunosuppression, absolute number of T cells is important • susceptibility to viral and protozoal infection • frequent mycotic infection – Aspergillus • good prophylaxis of intersticial pneumonia (Pneumocystis carinii) • problems with CMV, pneumonia – the most severe form, mortality cca 85% primary infection – transfer by CMV pos. donor reactivation – patient CMV pos. prior to Tx reinfection – CMV pos. patient infected with another strain systemic disease, gastroenteritis or hepatitis – good therapy, diagnostics improvement • adenoviral pneumonia Intermediate phase of infectious risk • HHV6 infection associated with pneumonia, delayed engraftment, prolonged thrombocytopenia and encephalitis detection of HHV6 DNA in blood during the first months after Tx – difficult to establish its implication in clinical symptoms qRT-PCR monitoring (not possible by antibody detection) • EBV associated lymphoproliferative disease life-threatening complication after Tx transfer from donor – testing the pair, prophylaxis in patient activation associated with patient‘s immunosuppression risk factor: T-cell depletion of the graft qRT-PCR monitoring (not possible by antibody detection) Late phase of infectious risk • from D+100 until the normalization of immune system • infectious complications↓ • risk factors result from persisting affected humoral and cellular immunity (normalization within 1 – 2 years post Tx) • defence against viruses↓ herpes zoster infection – usually mild, can be disseminated with lethal encephalitis or pneumonia • during GvHD: Streptococcus pneumoniae, Haemophilus influenzae infection long-term reduction of defence ability during cGvHD due to GvHD itself and immunosuppressive therapy Prevention and treatment of infection Body surface care antiseptic solutions for wiping, important mouth care (dental treatment prior to Tx, frequent washing out post Tx) GIT decontamination antibiotics against G - bacteria, antimycotics Lowbacterial diet water and food sterilization (bread in autoclave), heat-treated foods, scalable fruits Isolation of the patient rooms equipped with HEPA filters Nursing regimen staff – hats, mouthpieces, coats, gloves, overshoes incoming material decontamination Prevention and treatment of infection Surrounding care washing of areas, floor Microbial settlement monitoring bacteriologic examination of stool, urine and all body cavities Prophylaxis wide-spectrum antibiotics Immunotherapy passive immunotherapy – intravenous imnunoglobulines, hyperimmune globulines active immunization with specific vaccines cytokines like G-CSF, GM-CSF, interleukines, interferon Re-vaccination post Tx • immunization with live vaccines is dangerous post Tx patients are immunocompromised - not earlier than after 2 years, chronic GvHD contra-indication • possible to immunize with dead antigens - also in aGvHD, cGvHD Recommended immunization First year post Tx diphtheria, pertussis, tetanus H.influenzae, hepB, flu, Salk inactivated vaccine (poliomyelitis) Second year post Tx measles, mumps, rubella (if there is epidemiologic indication) Immunization of family members - within 1st year not with Sabin (attenuated live) vaccine against poliomyelitis - against measles, mumps and rubella don‘t threaten transplanted patients Late consequences of Tx consequence of conditioning regimen or GvHD – appearance even after several years post Tx Irradiation children reduced growth, failure in face structure and teeth creation (treatment with growth hormone) growth failures also after usage of Cy/Bu or long corticoid treatment of cGvHD later puberty in girls, hormonal treatment females usually infertile after irradiation, pregnancy rare males without mature sperms, usually permanent restoration of spermatogenesis after milder conditioning regimen radiating nephritis (also Cy, Mel, CsA, ATB participation) Late consequences of Tx • thyroid dysfunction after irradiation • chronic liver involvement in form of chronic GvHD, chronic active hepatitis and biliary cirrhosis • cataracts within 6 years after TBI at the dose of 10 Gy and above • reduced tears creation and eye dryness after irradiation • respiratory infections (CMV) also after termination of immunosuppressive therapy, activation of latent infection or primary infection during supportive treatment with blood products • frequent osteoporosis after treatment with corticoids artificial menopause, cGvHD • secondary malignant diseases due to chemo/radiotherapy, immunosuppression or transplant itself (stem cells with malignant potential) Late consequences of Tx • rarely myastenia gravis and polymyositis • psychological, psycho-social and social problems anxiety, small self-confidence, fear of relapse, dependence on medical staff and family, sexual problems, fear of financial problems due to long-term treatment, etc. Late consequence monitoring recommended examinations for physicians outside Tx unit, long-term patient monitoring post Tx Recommended examinations • • • • • • • • • • • • • skin, oral mucosa, teeth, eyes and joints (GvHD symptoms) weight overall blood counts rtg of lungs, lung function liver and renal function thyroid gland function (TSH, T3) FSH, LH, estrogens, growth hormone, testosterone blood group and antibody titer (after AB0 incompatibile Tx) myelogram every 2 months, later every 6 – 12 months gynecologic examination (prescription of hormonal supportive treatment) eye examination (exclusion of sicca syndrome and cataract development) in children height and weight compared to standard psychological consultations Case report 1 • female, 3 years (dg. ovarian tumor) • no siblings • sec. AML M5 diagnosed after anamnesis of hyperleukocytosis (95% of blasts in PB), anemia, hyperuricemia, neck and mezenterial lymphadenopathy • early isolated bone marrow relapse 7 months after start of chemotherapy AML BFM protocol, further chemotherapy AML REZ protocol – complete remission • MUD HSCT (PBSC) in 2nd CR donor: F/25, 10/10 match Conditioning regimen FLAMSA (Amsacrine, Fludara, ARA-C, fractionated TBI, Cyclophosphamide) GvHD prophylaxis Cyclosporine A, ATG, mycophenolate mofetil (MMF) Post Tx course • D+13 engraftment (granulocytes) • D+22 thorax rash, spread to neck and face, followed by subfebrilia, sulkiness, apepsia, mushy smelly stool • D+28 GvHD grade II (skin 1, GIT 1, liver 0) - corticoids 1 mg/kg repair, rash regression • D+42 reduction of corticoids to 0.6 mg/kg • D+44 discharged from hospital • D+69 corticoids discontinued • persisting hematologic remission, complete donor hematopoiesis Case report 2 • male, 7 years, CMV positive • HLA non-identical sister • c-ALL diagnosed after anamnesis of febrile infection with hemorrhagic diathesis, hepatosplenomegalia, hyperleukocytosis • chemotherapy: good response • early isolated bone marrow relapse (21.5 months from diagnosis) → combined chemotherapy, end of chemotherapy followed by aplasia, hyperbilirubinemia • MUD HSCT (BM) in 2nd CR donor: M/28, 10/10 match Conditioning regimen fractionated TBI, etoposide GvHD prophylaxis cyclosporine A, ATG, methotrexate Post Tx course • after Tx severe mucositis grade III • D+10 veno-occlusive disease after anamnesis of interstitial liquid, hyperbilirubinemia, weight gain, refractory thrombocytopenia, hepatomegalia, ascites • D+21 autologous hematopoiesis 1% • D+23 engraftment (leukocytes) • D+28 complete donor hematopoiesis • D+48 CMV re-activation • D+57 discharged from hospital • persisting hematologic remission, complete donor hematopoiesis – intermittently autologous to 1%